Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias

被引:241
作者
Abdel-Wahab, Omar [1 ,2 ]
Manshouri, Taghi [4 ]
Patel, Jay [1 ]
Harris, Kelly [1 ]
Yao, JinJuan [3 ]
Hedvat, Cyrus [3 ]
Heguy, Adriana [1 ]
Bueso-Ramos, Carlos [5 ]
Kantarjian, Hagop [4 ]
Levine, Ross L. [1 ,2 ]
Verstovsek, Srdan [4 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10065 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
关键词
TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; MYELOID METAPLASIA; MUTATION; DISORDERS; MYELOFIBROSIS; MECHANISMS; CLONALITY; TET2;
D O I
10.1158/0008-5472.CAN-09-3783
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The oncogenetic events that transform chronic myeloproliferative neoplasms (MPN) to acute myeloid leukemias (AML) are not well characterized. We investigated the role of several genes implicated in leukemic transformation by mutational analysis of 63 patients with AML secondary to a preexisting MPN (sAML). Frequent mutations were identified in TET2 (26.3%), ASXL1 (19.3%), IDH1 (9.5%), and JAK2 (36.8%) mutations in sAML, and all possible mutational combinations of these genes were also observed. Analysis of 14 patients for which paired samples from MPN and sAML were available showed that TET2 mutations were frequently acquired at leukemic transformation [6 of 14 (43%)]. In contrast, ASXL1 mutations were almost always detected in both the MPN and AML clones from individual patients. One case was also observed where TET2 and ASXL1 mutations were found before the patient acquired a JAK2 mutation or developed clinical evidence of MPN. We conclude that mutations in TET2, ASXL1, and IDH1 are common in sAML derived from a preexisting MPN. Although TET2/ASXL1 mutations may precede acquisition of JAK2 mutations by the MPN clone, mutations in TET2, but not ASXL1, are commonly acquired at the time of leukemic transformation. Our findings argue that the mutational order of events in MPN and sAML varies in different patients, and that TET2 and ASXL1 mutations have distinct roles in MPN pathogenesis and leukemic transformation. Given the presence of sAML that have no preexisting JAK2/TET2/ASXL1/IDH1 mutations, our work indicates the existence of other mutations yet to be identified that are necessary for leukemic transformation. Cancer Res; 70(2); 447-52. (C)2010 AACR.
引用
收藏
页码:447 / 452
页数:6
相关论文
共 17 条
  • [1] Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
    Abdel-Wahab, Omar
    Mullally, Ann
    Hedvat, Cyrus
    Garcia-Manero, Guillermo
    Patel, Jay
    Wadleigh, Martha
    Malinge, Sebastien
    Yao, JinJuan
    Kilpivaara, Outi
    Bhat, Rukhmi
    Huberman, Kety
    Thomas, Sabrena
    Dolgalev, Igor
    Heguy, Adriana
    Paietta, Elisabeth
    Le Beau, Michelle M.
    Beran, Miloslav
    Tallman, Martin S.
    Ebert, Benjamin L.
    Kantarjian, Hagop M.
    Stone, Richard M.
    Gilliland, D. Gary
    Crispino, John D.
    Levine, Ross L.
    [J]. BLOOD, 2009, 114 (01) : 144 - 147
  • [2] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
    Baxter, EJ
    Scott, LM
    Campbell, PJ
    East, C
    Fourouclas, N
    Swanton, S
    Vassiliou, GS
    Bench, AJ
    Boyd, EM
    Curtin, N
    Scott, MA
    Erber, WN
    Green, AR
    [J]. LANCET, 2005, 365 (9464) : 1054 - 1061
  • [3] Mechanisms of disease: The myeloproliferative disorders
    Campbell, Peter J.
    Green, Anthony R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) : 2452 - 2466
  • [4] Mutation of JAK2 in the myeloproliferative disorders:: timing, clonality studies, cytogenetic associations, and role in leukemic transformation
    Campbell, Peter J.
    Baxter, E. Joanna
    Beer, Philip A.
    Scott, Linda M.
    Bench, Anthony J.
    Huntly, Brian J. P.
    Erber, Wendy N.
    Kusec, Rajko
    Larsen, Thomas Stauffer
    Giraudier, Stephane
    Le Bousse-Kerdiles, Marie-Caroline
    Griesshammer, Martin
    Reilly, John T.
    Cheung, Betty Y.
    Harrison, Claire N.
    Green, Anthony R.
    [J]. BLOOD, 2006, 108 (10) : 3548 - 3555
  • [5] Mutations of ASXL1 gene in myeloproliferative neoplasms
    Carbuccia, N.
    Murati, A.
    Trouplin, V.
    Brecqueville, M.
    Adelaide, J.
    Rey, J.
    Vainchenker, W.
    Bernard, O. A.
    Chaffanet, M.
    Vey, N.
    Birnbaum, D.
    Mozziconacci, M. J.
    [J]. LEUKEMIA, 2009, 23 (11) : 2183 - 2186
  • [6] Mutation in TET2 in Myeloid Cancers
    Delhommeau, Francois
    Dupont, Sabrina
    Della Valle, Veronique
    James, Chloe
    Trannoy, Severine
    Masse, Aline
    Kosmider, Olivier
    Le Couedic, Jean-Pierre
    Robert, Fabienne
    Alberdi, Antonio
    Lecluse, Yann
    Plo, Isabelle
    Dreyfus, Francois J.
    Marzac, Christophe
    Casadevall, Nicole
    Lacombe, Catherine
    Romana, Serge P.
    Dessen, Philippe
    Soulier, Jean
    Viguie, Franck
    Fontenay, Michaela
    Vainchenker, William
    Bernard, Olivier A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (22) : 2289 - 2301
  • [7] GAIDANO G, 1994, LEUKEMIA, V8, pS27
  • [8] A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
    James, C
    Ugo, V
    Le Couédic, JP
    Staerk, J
    Delhommeau, F
    Lacout, C
    Garçon, L
    Raslova, H
    Berger, R
    Bennaceur-Griscelli, A
    Villeval, JL
    Constantinescu, SN
    Casadevall, N
    Vainchenker, W
    [J]. NATURE, 2005, 434 (7037) : 1144 - 1148
  • [9] A gain-of-function mutation of JAK2 in myeloproliferative disorders
    Kralovics, R
    Passamonti, F
    Buser, AS
    Teo, S
    Tiedt, R
    Passweg, JR
    Tichelli, A
    Cazzola, M
    Skoda, RC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) : 1779 - 1790
  • [10] Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
    Levine, RL
    Wadleigh, M
    Cools, J
    Ebert, BL
    Wernig, G
    Huntly, BJP
    Boggon, TJ
    Wlodarska, L
    Clark, JJ
    Moore, S
    Adelsperger, J
    Koo, S
    Lee, JC
    Gabriel, S
    Mercher, T
    D'Andrea, A
    Fröhling, S
    Döhner, K
    Marynen, P
    Vandenberghe, P
    Mesa, RA
    Tefferi, A
    Griffin, JD
    Eck, MJ
    Sellers, WR
    Meyerson, M
    Golub, TR
    Lee, SJ
    Gilliland, DG
    [J]. CANCER CELL, 2005, 7 (04) : 387 - 397